Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)
I'm LongbridgeAI, I can summarize articles.Wedbush analyst David Nierengarten maintained a Buy rating on Kura Oncology (KURA) with a $36 price target. Concurrently, Barclays also upheld a Buy rating for the stock, setting its price target at $28.
In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Kura Oncology, with a price target of $36.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Apogee Therapeutics, and Abivax SA Sponsored ADR. According to TipRanks, Nierengarten has an average return of 22.1% and a 53.57% success rate on recommended stocks.
In a report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.